Company Filing History:
Years Active: 2019
Title: Innovations of Inventor Xing Cai
Introduction
Xing Cai is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of biotechnology, particularly in cancer research. His work focuses on the use of microRNA in therapeutic applications.
Latest Patents
Xing Cai holds a patent for the "Use of miRNA-214 inhibitor in inhibiting regulatory cells." This patent describes the application of miRNA-214 inhibitors to suppress regulatory T cells (Treg cells). The research indicates that miRNA-214 promotes Treg cell growth, which can aid tumors in evading the immune system. By inhibiting miRNA-214, the growth of Treg cells can be reduced, thereby inhibiting tumor growth. This discovery opens avenues for developing anti-tumor drugs or treatments that counteract hyperactive immune responses.
Career Highlights
Xing Cai is associated with Jiangsu Micromedmark Biotech Co., Ltd., where he continues to advance his research. His innovative approach to utilizing miRNA in cancer treatment has positioned him as a key figure in the biotechnology sector.
Collaborations
Xing Cai collaborates with talented individuals such as Chenyu Zhang and Ke Zeng, contributing to a dynamic research environment.
Conclusion
Xing Cai's work exemplifies the potential of microRNA in cancer therapy, showcasing his commitment to innovation in biotechnology. His contributions are paving the way for future advancements in anti-tumor drug development.